Ardelyx Inc (ARDX) - Total Liabilities
Based on the latest financial reports, Ardelyx Inc (ARDX) has total liabilities worth $355.88 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ardelyx Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Ardelyx Inc's total liabilities have evolved over time, based on quarterly financial data. See Ardelyx Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Ardelyx Inc Competitors by Total Liabilities
The table below lists competitors of Ardelyx Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangzhou Hexin Instrument Co Ltd
SHG:688622
|
China | CN¥464.96 Million |
|
SLC Agrícola S.A
SA:SLCE3
|
Brazil | R$15.69 Billion |
|
Companhiade Eletricidade do Estado da Bahia - COELBA
SA:CEEB3
|
Brazil | R$24.81 Billion |
|
Beijing Gehua CATV Network Co Ltd
SHG:600037
|
China | CN¥2.84 Billion |
|
Rackspace Technology Inc
NASDAQ:RXT
|
USA | $3.98 Billion |
|
Direcional Engenharia S.A.
SA:DIRR3
|
Brazil | R$9.70 Billion |
|
Olaplex Holdings Inc
NASDAQ:OLPX
|
USA | $582.21 Million |
|
Shinkong Synthetic Fiber Corp
TW:1409
|
Taiwan | NT$168.08 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Ardelyx Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ARDX market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ardelyx Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ardelyx Inc (2012–2025)
The table below shows the annual total liabilities of Ardelyx Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $334.65 Million | +27.50% |
| 2024-12-31 | $262.46 Million | +100.72% |
| 2023-12-31 | $130.76 Million | +42.54% |
| 2022-12-31 | $91.74 Million | +36.32% |
| 2021-12-31 | $67.30 Million | -10.81% |
| 2020-12-31 | $75.45 Million | +3.18% |
| 2019-12-31 | $73.13 Million | +8.31% |
| 2018-12-31 | $67.52 Million | +263.18% |
| 2017-12-31 | $18.59 Million | -6.95% |
| 2016-12-31 | $19.98 Million | +148.35% |
| 2015-12-31 | $8.04 Million | -84.74% |
| 2014-12-31 | $52.73 Million | +4.99% |
| 2013-12-31 | $50.23 Million | +28.39% |
| 2012-12-31 | $39.12 Million | -- |
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on… Read more